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ClassiﬁersBiomarker development for prediction of patient response to therapy is one of the goals of molecular proﬁling of
human tissues. Due to the large number of transcripts, relatively limited number of samples, and high variability
of data, identiﬁcation of predictive biomarkers is a challenge for data analysis. Furthermore, many genes may be
responsible for drug response differences, but often only a few are sufﬁcient for accurate prediction. Here we
present an analysis approach, the Convergent Random Forest (CRF) method, for the identiﬁcation of highly
predictive biomarkers. The aim is to select from genome-wide expression data a small number of non-redundant
biomarkers that could be developed into a simple and robust diagnostic tool. Our method combines the Random
Forest classiﬁer and gene expression clustering to rank and select a small number of predictive genes. We
evaluated theCRF approach by analyzing four different data sets. Theﬁrst set contains transcript proﬁles ofwhole
blood from rheumatoid arthritis patients, collected before anti-TNF treatment, and their subsequent response to
the therapy. In this set, CRF identiﬁed 8 transcripts predicting response to therapy with 89% accuracy. We also
applied the CRF to the analysis of three previously published expression data sets. For all sets, we have compared
the CRF and recursive support vector machines (RSVM) approaches to feature selection and classiﬁcation. In all
cases the CRF selects much smaller number of features, ﬁve to eight genes, while achieving similar or better
performance on both training and independent testing sets of data. For both methods performance estimates
using cross-validation is similar to performance on independent samples. Themethodhas been implemented inR
and is available from the authors upon request: Jadwiga.Bienkowska@biogenidec.com.
© 2009 Elsevier Inc. All rights reserved.Introduction
Advances in high-throughput, genome-wide transcript proﬁling
technologiesmake it possible to investigate howmolecular features of
patients correlate with clinical disease subtypes and response to
treatment. Computational and statistical analysis of transcript
proﬁling (or proteomic) data from large patient populations can be
used to ﬁnd classiﬁers that differentiate among patient groups of
clinical interest. One goal of this type of research is the development
of molecular diagnostics that predict which drugs will be most
beneﬁcial to speciﬁc patients. Recently, several statistical methods
[1–3] have been introduced to address the problems of classiﬁcation
and feature selection using gene expression data. The classiﬁcation of
a clinical parameter, such as disease subtype or responder vs. non-
responder, is accomplished using several molecular features, i.e. gene
expression. One of the challenges is to design a robust classiﬁcation
algorithm that will perform well on unseen data. Another challenge isnIdec, 14 Cambridge Center,
(J.R. Bienkowska).
ll rights reserved.to select features (genes) that are unique, consistent, and non-
redundant with a high aggregate predictive accuracy. Identifying a
small set of genes is especially useful for the development of a clinical
diagnostic where simple and robust technologies are needed.
In this paper, we introduce a newmethodology to construct a robust
classiﬁer as well as to select the minimum number of genes with maxi-
mum prediction performance. For classiﬁcation we used the random
forest (RF) algorithm, a machine learning technique introduced by
Breiman [4], shown to outperform most of the other classiﬁcation
techniques in different tasks [2,5–9]. The RF approach builds a number
of decision trees ntree from randomly selected sets of genes-mtry and
about 2/3 of the samples. The rest of the samples are called out-of-bag
samples and the error rate calculated from the prediction of these
samples is called the out-of-bag error (OOBerror). OOBestimate of error
rate was reported to be quite accurate and unbiased [10] since the
information provided by out-of-bag samples is not used to build the
trees. The RF approach also calculates the inﬂuence of each variable (e.g.
gene expression) to the predictions, called variable importance [4].
Although the RF is a very powerful statisticalmethod, the challenges
presented by gene expression data sets are not easily overcome by a
standard application of the algorithm. Themain challenge is the curse of
424 J.R. Bienkowska et al. / Genomics 94 (2009) 423–432dimensionality presented by gene expression data with relatively few
samples (∼100 patients) to be classiﬁed by amuch larger set of features
(∼30,000 gene expression values). Thus, simultaneous reduction of the
dimensionality of the data and retention of the differentiating features is
one of the objectives of our approach. We address these challenges by
ﬁrst identifying theoptimal algorithmparameters for adata set and then
by introducing a new method for selection of the most predictive
features. We identify the best features by applying a converging RF
algorithm and select the most predictive genes with cluster cutting,
where gene expression correlations are taken into account. The RF
algorithmwas reported to performwell with its default parametermtry
(number of random variables) [10], however there is no study compre-
hensively evaluating the dependence of its performance on the para-
meters. Here, we present a general methodology to select the best
parameters to construct a stable RF classiﬁer.
Another challenge in designing the best predictor is feature
(gene transcript) selection. Feature selection algorithms typically use
one of two approaches: (1) recursive gene ﬁltering/shaving and (2)
frequency-basedgene ranking. Recursive geneﬁlteringhasbeenapplied
by van't Veer et al. [11], in a variant of support vector machines (SVM)
known as SVM recursive feature elimination (SVM-RFE) [1], and also in
the context of Random Forest [12,13]. Zhang et al. [14] developed a
recursive support vector machine (R-SVM) algorithm that is similar to
SVM-RFE but selects important features based on frequency. They
showed that RSVM outperforms SVM-RFE in the robustness to noise as
well as in recovery of informative features, and has better accuracy on
independent test data. Here, we deﬁne a frequency-based Gene Predic-
tive Index that is used for gene selection.
In this paper, we introduce an algorithm thatﬁrst constructs a robust
random forest classiﬁer with optimal parameters and then selects the
minimum number of genes with maximum accuracy in predicting
response. To construct a stable classiﬁer we evaluate the effects of
different parameters on the random forest error rate, and introduce a
methodology to select the best parameters. With the optimal para-
meterswe ﬁnd a set of predictive genes. To select theminimumnumber
of genes from this set, we introduce a novel clustering-based gene
selection method that uses frequency to rank genes. The frequency
ranking ensures that selected genes are consistently important in
prediction, while the clustering approach selects an uncorrelated and
non-redundant small set of genes with high prediction capability. The
variability of the lists of the most predictive genes has been noted
previously [15] andwas shown to dependon the training set. It has been
also shown that, despite this variability, different best gene sets perform
well on independent samples sets [16]. Here, we use the random
sampling of the RF to capture this variability and identify all of the best
predictive genes.
We applied our algorithm to a data set of whole blood gene ex-
pression proﬁles for 46 rheumatoid arthritis (RA) patients. The blood
was collected from thepatients before the start of anti-TNF therapywith
one of three approved drugs: etaneracept, inﬂixmab, or adalimumab.
Patients' response to therapy was assessed after a 3-month treatment.
The CRF approach identiﬁed a pre-treatment eight-gene signature that
predicts response to therapywith 89% accuracy and has been replicated
with a small independent set of samples. This ﬁnding demonstrates the
feasibility of development of a molecular diagnostic for use in the
medical care of RA patients with anti-TNF therapies.
To show the general utility of our approach we have also applied
the CRF to three previously published expression data sets and have
compared with the recursive SVM (RSVM) method for feature
selection and classiﬁcation [15]. We have evaluated the performance
of both methods using independent testing sets of samples that were
not used in any step in the training process or feature selection. In all
cases, the CRF selects a much smaller number of features (5–8 genes)
as compared to RSVM (60–80 genes) and in most cases has better
performance as measured by the area under the receiver operating
characteristic (ROC) curve (AUC).Results
Overview of the method
We consider as an input data a set of gene expression proﬁles
representing Ns samples classiﬁed into response or disease categories
Rs. Ng is the number of transcripts relevant to the tissue type and
disease that are to be considered as predictive features. Design of the
Convergent Random Forest Predictor follows in three main steps. (1)
Selection of the Random Forest parameters optimal for the data set.
(2) Identiﬁcation of subset NPgbNg genes consistently predictive of
the response categories. (3) Ranking and selection of most predictive
genes MPgbb NPg and selecting the ﬁnal classiﬁer. Here, NPg is the
number of predictive genes and MPg is the number of most predictive
genes from which the predictors are built.
Step 1: ﬁnding optimal parameters for random forest
Two parameters are important in the random forest algorithm: the
number of trees used in the forest (ntree) and the number of random
variables used in each tree (mtry). Initial investigation of the OOB
errors determined that performance of the classiﬁer is much more
sensitive to the number of trees than themtry values. Thus we ﬁrst set
themtry to the default valuemtryd =
ﬃﬃﬃﬃﬃﬃ
Ng
p
and search for the optimal
ntree value. To ﬁnd the number of trees that correspond to a stable
classiﬁer, we build RF with different ntree values i.e. ntreei={1, 500,
1000…., 120,000}. We build 10 RF classiﬁers for each ntree value,
record the OOB error rate and calculate the median and standard
deviation of the error rate,m.OOB[ntreei] and sdv.OOB[ntreei]. First we
identify the minimal value of ntree where m.OOB[ntreei] and sdv.OOB
[ntreei] stabilize:
ntreeO =
argmax
ntreei
argminntreei m:OOB ntreei½ Vminntreej N ntreei m:OOB ntreej
h i  
argminntreei sdv:OOB ntreei½ Vminntreej N ntreei sdev:OOB ntreej
h i  
0
@
1
A
ð1Þ
We set the ntree value to the optimal as described above and proceed
to the search for optimal mtry.
To ﬁnd the optimummtry, we apply a similar procedure such that
RF is run 10 times for a range ofmtry values which consist of multiples
of the default (mtryd =
ﬃﬃﬃﬃﬃﬃ
Ng
p
) starting from 0.05xmtryd up to
mtry=Ns with increments of 0.05. At each run the OOB error rate is
recorded. The optimum mtry value(s) is selected for which the error
rate has stabilized and reached minimum. The following formula
deﬁnes the mtry values that correspond to the minimums:
mtryO = arg min
mtryka mtrymf g
ð mtrymf g = arg min
mtryi i=2:::Nsð Þ
m:OOB½mtryið Þ;
arg min
mtryka mtrymf g
ð jm:OOB mtryk½ − m:OOB mtryk−1½ j
+ jm:OOB mtryi½ − m:OOB mtryk + 1
  j + sdv:OOB mtryk½  jÞÞ
ð2Þ
where m.OOB[mtryi] is the median OOB error rate and sdv.OOB[mtryi]
is the standard deviation. Eq. (2) selectsmtryO values that satisfy both
the lowest error rate and the highest stability. In practice this equation
may identify more than one optimal mtryO value. For the optimal
values that differ by one we select the smaller mtryO.
Step 2: selecting genes consistently important in prediction
With the optimal values of ntreeO and mtryO as parameters, we
apply the Convergent Random Forest algorithm to select predictive
genes. The RF is run 10 times with each variable (gene) assessed by its
importance. From each runwe record genes with positive importance,
those that improve the prediction accuracy. Next, we select genes
common for all 10 runs. We iterate over the batches of 10 RFs each
425J.R. Bienkowska et al. / Genomics 94 (2009) 423–432time recording the predictive gene list Pig from the batch i as only
those that are in common with the previous batch i-1,PlgpP
l − 1
g . We
stop the iteration at i=imax, when the list from subsequent batches
are identicalPimaxg uP
imax − 1
g . The P
imax
g is the list of consistently
predictive genes. This procedure is repeated for all mtryO and the set
of predictive genes NPg is the set common to all values.
Step 3: selecting minimum number of genes with maximum prediction
accuracy
The last step of the algorithm identiﬁes amongNPg genes selected in
step 2 those that predict the responses with maximum accuracy. The
gene selection/ﬁltering algorithm derives from the observation that
predictive genes correlate with each other and thus the complete list of
predictive genes includes redundancies. Moreover, the response signal
encoded in each expressionvalue is confoundedbynoise and combining
many genes in the predictor accumulates the noise. For selecting the
best predictive transcripts (genes) we apply two approaches. Both
approaches use the importance of the gene as calculated by the RF. The
ﬁrst approach, selection by importance, starts with the most important
gene, adds one gene at a time and calculates the OOB-error. The second,
selectionwith clustering approach startswithgenes clustered according
to their expression correlation across the samples, then we recursively
cut the cluster into k sub-clusters and select from each sub-cluster the
gene with the highest rank by importance. For each k we build a
predictor from the selected genes and calculate the OOB error. This
procedure is repeated several times and each time the set of predictor
genes with smallest OOB-error is recorded. In this step we use the
defaultmtry value that is equal to
ﬃﬃﬃﬃﬃﬃﬃﬃ
NPg
p
.
Below is the pseudo-code for the two selection procedures. First
we rank the genes g1, g2,.., gn, according to variable importance in
decreasing order with ri denoting the rank of the gene gi .
Selection of best predictor genes based on importance ranking.
(1) Set x=1.
(2) Select x top genes Gx = [i gi; riVxf g and calculated OOB[x]
error for gene set Gx
(3) Set x=x+1. Repeat from Step 3 until x=n.
(4) xmin = argminx OOB x½ ð Þ. There can be several values of x with
the lowest error.Selection based on clustering
(1) Cluster the genes using the correlation of the gene expression
values as the distancematrix. Set the number of clusters to k=2.
(2) Cut the dendrogram into k clusters, and select the highest
ranking gene from each cluster. Those genes make the k-
clusters gene set Gk = [k
j=1
argmaxgiaCj rið Þ, where C
j denotes
the j-th cluster (see supplementary Fig. 4). Next, calculate OOB
[k] error for gene set Gk.(3) Set k=k+1. Repeat from Step 2 until k=min(xmin) (see
Selection based on importance ranking).
(4) kmin = argmink OOB k½ ð Þ. Select k-genes that have minimum
OOB error rate.Ranking the most predictive genes with gene predictive index (GPI)
For ranking the most predictive genes we iterate over the
following procedure and record results from each iteration i.
• Select genes based on importance ranking and minimal error rate.
Let Gxmini denote the set of selected genes with minimal error rate
OOB[xmin] and jGxmini j the cardinality of this set.
• Select genes based on clustering and minimal error rate. Let Gkmini
denote the set of selected genes with minimal error rate OOB[kmin]
and jGkmini j the cardinality of this set.The ﬁnal set of most predictive genes MPg is the union of all best
gene subsets identiﬁed in the iterations:
MPg = [
i
Gxmini [ G
kmin
i ð3Þ
The Gene Predictive Index (GPI) for each gene g from the MPg set is
given by the following formula:
GPI gð Þ =
X
i
1− OOB xmin½ 
jGxmini j
+
X
i
1− OOB kmin½ 
jGkmini j
 !
=max ið Þ ð4Þ
Thus if the number of most predictive genes including gene g
identiﬁed in an iteration is small, that gene is given a higher index.
Moreover, as the frequency of appearance of the gene in the runs
increases, GPI of the gene also increases (through summation). Genes
are ranked according to GPI in decreasing order. The maximum value
of the GPI is 2 in a hypothetical best case when a perfect prediction
(zero error) is obtained with a single gene transcript. As the ﬁnal step
in constructing the predictor we rank genes by the GPI and adding one
at a timewe calculate the OOB error for the ﬁrst k-best genes. The ﬁnal
predictor is the one with the smallest error and number of genes. In
practice this number is a fraction of the total number of all the best
genes ranked by the GPI.Example I: prediction of response to TNF-blockade in rheumatoid
arthritis
We applied the method of designing a Convergent Random Forest
Predictor to gene expression proﬁles of whole blood samples from
rheumatoid arthritis patients provided by the Autoimmune Biomar-
kers Collaborative Network (ABCoN). The blood was collected before
patients began TNF-blockade treatment with adalimumab, etaner-
cept, or inﬂiximab. Patients' response, or the change in disease
activity, was measured after 14 weeks according to standards of
clinical practice. The details about the sample collection, processing,
and deﬁnition of responsive and non-responsive patients are in
Supplementary material. Our initial gene selection procedure is very
stringent and in this case has the false discovery rate of 10−10. Initial
data processing and gene ﬁltering resulted in 166 gene transcripts
that are signiﬁcantly correlated with anti-TNF response, as described
in Supplementary materials and methods. Starting from 166 tran-
scripts, our primary goal was to ﬁnd a stable predictor with a
minimum number of genes and maximum performance. The accuracy
of the RF predictor constructed with 166 transcripts is 68%. Similar
accuracy (76%) is achieved with 36 genes that are signiﬁcantly
differentially expressed between responders and non-responders at
pre-treatment visit. This level of accuracy is insufﬁcient to pursue the
development of clinical diagnostic tools that would clearly beneﬁt
patients. To support a recommendation to change treatment to a
different drug, a predictive accuracy of more than 80% is desirable. To
improve the prediction accuracy to N80%, we applied the Convergent
Random Forest Predictor design method to this data set.
Selecting optimal parameters
We searched for the optimum number of trees with a stable
classiﬁer i.e. the performance does not change asmore trees are added
to the forest. For this we ran RF 10 times for different ntree values and
defaultmtry=13, each time recording the OOB error rate. Themedian
and the standard deviation (std) across these 10 runs and different
ntree values are shown in supplementary Fig. S1a and S1b,
respectively. In this data set the median error rate stabilized quickly
while the standard deviation continued to decline as more trees were
added to the forest. Therefore, the application of Eq. (1) selected the
optimal ntree after which the standard deviation stabilized (Fig. S1.b)
ntreeO=15400. Since small differences in the number of trees have no
Fig. 2. Change of OOB error rate with the number of genes selected by two methods
importance and clustering ranking in one example run of the RF. The black line
corresponds to genes selected by importance ranking of the initial 166 genes set. Blue
circles represent 40 convergent genes ranked by the importance measure. Minimum
error (11%) is obtained with k=24 genes, circled in red. Red circles correspond to the
error rate with k-best genes selected from k clusters (x axis). Minimum error (11%) is
obtained with k=8 genes, circled in red.
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next step. The question arises whether we could be over-ﬁtting with
this number of trees. Two things guard us against over-ﬁtting; ﬁrst
each step of the random forest performs a cross-validated search
internal to the procedure, as it has been proven by Breiman [4].
Second, given the number of variables 166, and the number of sam-
ples the possible number of different trees is 1053, a number many
orders of magnitude larger than 16,000 trees. Additionally, since each
tree is built from randomly selected samples and variables even if we
built very large number of trees (NN16000) it is unlikely to exhaus-
tively sample all possibilities.
Next we selected the optimal mtry value. For this, RF was run 10
times for a range of mtry values with OOB error rate recorded at each
run. The change of median and standard deviation of error rate with
mtry is shown for ntree=16,000 (supplementary Fig. S2). Since we
selected ntree for which the standard deviation stabilized at the
previous step, the standard deviation differences are very small for
different mtry (Fig. S2b). We chose optimal mtryO values based on
error rate and stability as deﬁned by Eq. (2). For this data set the
mtryO={45}. The supplementary Fig. S2 illustrates that mtry affected
the performance but had much smaller inﬂuence than ntree. The
change of OOB error rate with mtry was independent of ntree
(Supplementary Fig. S3), as previously noted in [12].
Selecting genes consistently important in prediction
The “convergent random forest” algorithm (see Step 2 of our
method) was run using the mtry={45}. With thismtry, the algorithm
resulted in a “convergent”ﬁnal set of 40 transcripts. The performanceof
each set was then calculated with 10 independent RF runs. The results
are shown in Fig. 1 for ntree=16,000. The ﬁrst panel (a-45) shows
the performance of all 166 transcripts as the initial set. The second
panel (f-45) shows the performance of the ﬁnal 40 transcripts. For
comparison, we ran RF, ranked the transcripts based on importance,
and selected the top 40 transcripts without applying convergence. The
third panel (imp-45) shows the performance of 40 transcripts selected
using the same mtry value. Our ﬁnal set of 40 transcripts is largely
overlapping with the top most important 40 transcripts, however a
prioriwe could not know how many top genes to select.
The second panel in Fig. 1 shows that ﬁltering genes using the
convergence method reduces the error rate from 26–30% to 18–21%
with respect to the initial 166 gene set (compare with the ﬁrst panel).
Comparison of the performance of the convergence method with that
of selection of the top important genes (see Fig. 1, f-45 versus imp-45)
shows that the ﬁnal convergent set is at least as good as the same
number of top important genes. Yet, the convergence method is more
stringent and more reliable than the latter because: (1) it is unbiased
since the number of ﬁnal genes is not determined a priori (2) it selects
genes based on not just one ranking but based on consistency of
rankings which was shown to perform well in the recursive-SVM
method [14] with respect to state-of-the-art SVM-RFE [1].Fig. 1. Error rate distributions at mtry={45} (10 runs each) for three gene groups: (a-
45) all 166 genes (f-45) ﬁnal 40 genes that converged at mtry={45} (imp-45) ﬁrst 40
genes selected by importance among 166.Overall, the classiﬁer with 40 transcripts selected by convergence
resulted in an improved accuracy (80% accuracy atmtry=45) relative
to the initial 166 set (68%).
Selecting minimum number of genes with maximum prediction accuracy
Starting with the convergent gene set (40 transcripts) and default
mtry=6 we calculated the importance of each gene. First the change
of error rate is calculated with the increasing number of genes
selected by the importance measure (Fig. 2, blue line). Fig. 2 shows an
example run and changes in error as one gene at a time is added to the
predictor using different selection methods. We note that every run
has a slightly different proﬁle of errors due the randomness of the
forest. In this example run, the minimum error rate (11%) was
obtained for the top 24most important genes (circled in Fig. 2), that is
the jGxmini j=24. Next we clustered 40 genes using the hierarchical
clustering with the correlation between gene expressions as a mea-
sure of distance. The clustering dendrogram is shown in supplemen-
tary Fig. S4. We recursively cut the dendrogram into k=2, 3, 4, 5….
jGxmini j sub-clusters (24 in this example run). For each of the k-
subclusters a transcript with the highest importance for classiﬁcation
is selected. For k-subclusters we have thus k-best transcripts. The
performance of the RF predictors constructed from k-best genes is
shown in Fig. 2 (red line). The selection of kmin=8 resulted in the
best performance of the RF predictor with accuracy of 89% (error rate
11%). We call these transcripts sets the “most predictive transcripts”
selected either by importance ranking or clustering.
The procedure of gene selectionwas repeated 50 times. At each run
we recorded the number of predictive genes obtained by importance
and cluster-based ranking. Fig. 3 shows the distribution of the number
of genes obtained from the twomethods in each of the 50 runs. A total
of 13 best gene sets withminimal OOB error were constructed in these
runs. The lowest OOB error rate was 11%. A set of 8 genes with the 11%
error ratewas selected 30 times by clustering and once by importance.
The next best gene set with the same accuracy contained 12 genes and
was selected 10 times by importance. These results indicate that a
conclusion based on one run could be misleading since different runs
resulted in a different number of geneswithminimum errorwith both
methods. Thus, the results from this procedure were combined to
identify all of the best predictive transcripts. The combination of all
predictive genes resulted in 24 gene transcripts. Using the gene
predictive index deﬁned in Eq. (3) we ranked the ﬁnal list of trans-
cripts. The results are given in the supplementary Table S1 with the
8 best predictor transcripts indicated at the top of the ranking.
As a ﬁnal step, we ran RF starting from the ﬁrst ranked gene (Table
S1), then adding the second, third, and so on until we added the ﬁnal
ranked gene. Each time we recorded OOB error rate. As shown in
Fig. 3. Number of genes (y axis) with minimum error (x axis) obtained by importance
ranking (red) and clustering (blue) in 50 separate random forest runs (z axis).
427J.R. Bienkowska et al. / Genomics 94 (2009) 423–432supplementary Fig. S5, the error rate levels off after theﬁrst 8 transcripts
and the maximum accuracy (89%) is obtained with 8 top ranked trans-
cripts, our best predictor. Among the 24 transcripts, 10were selected by
the clusteringmethod and all were selected by the importance ranking.
Overall the clustering selection is more consistent across iterations and
selects fewer genes than importance ranking, 10 versus 24.
In Table 1 we compare the sensitivity and speciﬁcity of the two
gene sets. The RF accuracy of the 24-gene set is slightly worse than the
accuracy of the best 8-gene predictor but the difference is not
signiﬁcant given the sample size. We also checked that a predictor
built using gene expression values estimated by the RMA [17] method
(we used the GCRMA initially) has the same accuracy (data not
shown). The ultimate goal is identiﬁcation of the biomarker set that
translates to a robust technology platform, such as Q-PCR, that could
be used in a clinical setting. It has been shown that for most
transcripts and probes designed to the same sequence regions Q-PCR
measurements correlate well with hybridization measurements of
expression (such as Affymetrix) [18–20]. Nevertheless one can expect
that some probe design will fail among 24 transcripts and thus it is
prudent to continue diagnostic development from this larger set of
24-genes while keeping focus on the 8-best genes.
Comparison of RF with other classiﬁcation methods
After a candidate gene set was determined, we then explored how
those genes perform with different classiﬁcation methods as listed inTable 1
Performance of the two best gene predictor sets.
Gene set Predicted Non-responder
8-genes NON-RESPONDER 20
RESPONDER 3
Accuracy 89% NPV 91% (CI 70%-98%)
24-genes NON-RESPONDER 19
RESPONDER 3
Accuracy 83% NPV 86% (CI 64%-96%)
BRASS Test set NON-RESPONDER 1
RESPONDER 1
Accuracy 83% NPV 50% (CI 3%-97%)
The prediction was done with the RF predictor and the accuracies were calculated with theMaterials and methods. In leave-one-out cross-validation tests we
compared the performance of the 8-gene, 24-gene and 40-gene sets
using different classiﬁcation methods. The error-rates for those gene
sets and methods are shown in the supplementary Table S2. For the
8-gene set several classiﬁcation methods reached accuracy greater
than 85%, including neural nets, linear discriminant analysis and
several variants of Support Vector Machines (SVMs). Linear kernel
SVM learning achieved the same accuracy of 89% as the RF. The RF
leave-one-out cross validation error is the same as the OOB error. The
24-gene set predictor built with two variants of SVM had the best
accuracy of 91%, however given the small number of samples these
differences are not signiﬁcant. These results demonstrate that
predictive accuracy of the selected genes does not dependent the
speciﬁc learning approach, the RF, used to identify them.
We have applied the 8-gene predictor to an independent set of
blood sample proﬁles provided by the Brigham andWomen's Hospital
Rheumatoid Arthritis Sequential Study (BRASS) registry of RA
patients. From the BRASS registry we obtained a small set of patients,
with no prior exposure to anti-TNF agents, for whom pre-treatment
gene expression data and anti-TNF response after 12 weeks were
available. This set consisted of 9 responsive and 2 non-responsive
patients. The BRASS blood samples were collected at a different site
and were processed with a slight different protocol than the ABCoN
samples. For the purpose of classifying BRASS patients we trans-
formed the log2 expression values of 8 genes into log2 expression
ratios of 7 genes: CLTB, MXRA7, CXorf52, COL4A3BP, YIPF6, BOD1L
and SFRS2, to PGK1 (one of the 8 genes) and constructed a predictor
with the same accuracy of 89% as the log2 expression-based predictor.
With the ratio-based predictor we predict correctly 9 of 9 responders
and 1 of the 2 non-responders (see Table 1), thus having 91% accuracy
on this independent sample set, similar as the OOB estimates.
However, due to a small representation of non-responders in the
test set the 95% conﬁdence margins are very large.
Example II: prediction of breast cancer metastasis
For the second application of the CRF predictor algorithm we have
chosen a data set ﬁrst analyzed by van't Veer et al. [12]. In the original
paper, gene expression proﬁles of fresh frozen primary tumor samples
from 78 breast cancer patients were analyzed. Patients were followed
for more than 5 years and the tumor metastasis time was reported.
Patients with time to metastasis shorter than 5 years (poor prognosis)
were assigned to one group and patients with time to metastasis
longer than 5 years were assigned to the second group. The goal of this
initial investigation was to determine the utility of gene expression
proﬁles as diagnostic tools for predicting future metastatic events.
This initial analysis has lead to the development of the MAMMAPRINT
diagnostic that was approved for clinical use in 2007 (Agendia™). The
original investigation identiﬁed 70 gene transcripts that predicted
progression to metastasis with 83% accuracy. The original work [12]
validated the 70-gene predictor by testing on 19 tumor samples thatResponder
2 Speci 91% (CI 69%–98%) Sens 88% (CI 67%–97%)
21
PPV 87% (65%-97%)
3 Spec 86% (CI 64%–96%) Sens 88% (CI 67%–97%)
21
PPV 88% (CI 67%-97%)
0 Spec 100% (CI 5%–100%) Sens 90% (CI 54%–99%)
9
PPV 100% (CI 63%-100%)
OOB cross-validation. 95% conﬁdence level intervals are included in parenthesis.
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the van't Veer data set was to determine whether the CRF algorithm
leads to identiﬁcation of a smaller number of genes with the same or
better accuracy as the original set.
The initial data processing (see Materials and methods) identiﬁed
223 genes as candidates for building the predictor. The ﬁrst step of the
CRF approach selected the optimal RF parameters for this set. The
optimal ntree valuewas at least 7510 trees while the optimalmtry=75.
For simplicity we used 10,000 trees in the second step of the algorithm
that identiﬁed genes consistently important for prediction. This step
identiﬁed 103 different transcripts, and their identiﬁers and
corresponding gene names are listed in the supplementary Table S3.
The third step of the CRF algorithm identiﬁed and ranked the 30 best-
predictive genes, which are listed in supplementary Table S4 with their
predictive indexes. Eight of those genes are also in the original 70-gene
set identiﬁed by van't Veer et al. [12]. As a ﬁnal step of the process we
built the predictor starting from the ﬁrst gene ranked by GPI and added
one gene at a time we found the best predictor. We found the best
predictor to have only 8 transcripts with 86% accuracy of predicting
progression tometastasis. Table 2 shows the performance of the 8 gene
predictor on the training set of 78 samples as well as the test set of 19
samples. The accuracy of our 8-gene predictor, correctly predicting
disease progression for 67 patients, is slightly better than the original
70-gene predictor. Additionally, the prediction accuracy of the 19 test
case samples is equivalent to the training set, with 16 patients' disease
progression predicted correctly.
Example III: leukemia subtypes
We have also tested the CRF approach using the data set of 72
leukemia samples ﬁrst analyzed by Golub et al. [21]. This set consists of
two subtypes of leukemia: acute lymphocytic leukemia (ALL) and acute
myeloid leukemia (AML). Gene expression data has been generated
using one of the earliest versions of Affymetrix arrays proﬁling 7129
genes. As in the original publication we use for training the set of 38
samples (27 ALL and 11 AML) and for testing the independent set of 34
samples (20 ALL and 14 AML). The data has been preprocessed as
described in Materials and methods and 512 probe sets were identiﬁed
as candidate biomarkers. The optimal ntree value for this data set was
identiﬁed as 2155 trees and for simplicity we used 2200 trees for the
next steps. Two optimal values of mtry were identiﬁed here mtryO=
{8,18}. With these values the convergent step of CRF identiﬁed 80
consistently predictive transcripts that are listed in the supplementary
Table S5. In the ranking and selection step 46 transcriptswere identiﬁed
and the top 8 transcripts on the list constitute the best predictor and are
shown in supplementary Table S6. The 8-gene predictor has accuracy of
100% on the training set and 89% on the test set.
Example IV: prostate cancer
Onemore data set that we have used for testing ourmethod is a set
of 52 prostate tumor and 50 normal prostate samples [22]. From this
set we have selected randomly 40 tumor and 40 normal samples forTable 2
Performance of the 8-gene RF predictor of poor or good metastasis prognosis.
Sample set Predicted Poor prognosis Good pr
Training 78 samples Poor prognosis 30 4
Good prognosis 7 37
Overall accuracy is 86% NPV=81% (CI 64%–91%) PPV=90
Testing 19 samples Poor prognosis 11 1
Good prognosis 2 5
Overall accuracy is 84% NPV=84% (CI 53%–97%) PPV=83
For the training set the accuracy was calculated with the OOB cross-validation. The predictor
level intervals are included in parenthesis.training and used the remaining 12 tumor and 10 normal samples for
testing as listed Materials and methods. These expression proﬁles
were generated using the hgu95a Affymetrix platform and represent
9000 genes. The initial preprocessing of the data described in the
Materials and Methods identiﬁed 921 gene transcripts as potential
biomarkers. The parameter optimization steps of the CRF identiﬁed as
optimal number of trees 1150, later on we use 1200 for simplicity. The
optimalmtryO={51,54} for this data set. The convergence step of the
CRF identiﬁed 79 transcripts that are listed in Table S7. The ranking
and ﬁnal selection step identiﬁed 16 genes and the top 5 of those
genes constitute the best predictor. The supplementary Table S8 lists
the ranking of these 16 genes. The 5-gene predictor has an accuracy of
96% on the training set and 95% on the test set.
Comparison of the CRF and RSVM feature selection methods
Using all 4 data sets described above we have compared the CRF
feature selection method and the recursive feature selection method
implemented by Zhang et al. [15] called RSVM.We selected RSVM as a
representative of other recursive feature selection methods as it is
readily available in R, an open source application, and has been shown
to perform slightly better than other recursive methods [15]. Since
CRF feature selection method is applied after the convergent set of
genes are identiﬁed, we have applied the RSVM method to the set of
genes identiﬁed after the convergence step: that is for the 40, 103, 80
and 79 genes identiﬁed for antiTNF response, BrCa metastasis,
leukemia and prostate cancer data sets. We have used for evaluation
of classiﬁers' performance the area under curve measure (AUC) of the
receiver operating characteristic (ROC). We used the BioConductor
package ROCR [23] for these calculations. The selection of features by
RSVM was implemented using the leave-one-out cross-validation
error in the training set. In Table 3 we list the number of features
selected by each method as well as the performance on the training
and testing sets. The training set performance is calculated for OOB
predictions of RF and leave-one-out cross-validation for the RSVM.
Overall, the CRF method has a better performance than the RSVM
method in all cases except the testing set of Leukemia subtypes where
the AUC difference between the two methods is small, 0.036. The
leukemia set is the only case where the RSVM method reduced the
convergent feature set from 80 to 60 genes, while in the other cases
the RSVMdid not identify a smaller number of predictive features. The
feature selection by CRF always identiﬁes much smaller number of
genes than RSVM. For three of four data sets the CRF selected 8 genes
and for the Prostate Cancer only 5. In all cases the performance
estimated on the training set is almost the same as that for testing set.
The largest difference between training and testing sets was for the
anti-TNF response prediction where the testing set contains only two
non-responders and nine responders.
Discussion
Different approaches have been developed for identiﬁcation of
biomarkers for disease classiﬁcation, prediction of disease progression,
and response to therapy.With genomic technologies one canmeasureognosis
Speciﬁcity=88% (CI 72%–96%) Sensitivity=84% (CI 69%-93%)
% (CI 75%–97%)
Speciﬁcity=91% (CI 60%–100%) Sensitivity=71% (CI 30%–95%)
% (CI 36%–99%)
trained on the 78 samples was applied to 19 independent test samples. 95% conﬁdence
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samples. The identiﬁcation of predictive biomarkers among thousands
of features is themain challenge for data analysis. One challenge posed
by the gene expression data is correlation of expressionmeasurements
across many genes. For samples that represent complex mixtures of
cells, such as blood, the noise in expression data is not randomly
distributed across the genes and samples. Thus the biomarker set
representing several groups of correlated genes, where the noise is
non-random, may be less accurate than a smaller set of un-correlated
genes. While developing the Convergent Random Forest Predictor we
followed the assumption that fewer genes will contain less noise and
will lead to a more accurate predictor. Furthermore, identiﬁcation of a
small number of biomarkers would allow implementation of bio-
marker diagnostics using robust and sensitive technologies such as
Q-PCR in contrast to less sensitive hybridization technologies used for
large numbers of transcripts.
With respect to classifying patients, gene expression in tissue
samples contains signal and noise. The signal may contain information
about the patient's future response to therapy. The noise comes from
several sources that may affect each gene differently but not
necessarily in a random pattern. The conspicuous sources of noise
are different genetic, dietary, health history and other patient
backgrounds that are difﬁcult to control or to take into account in
the study design and data analysis. We thus expected that a set of few
genes accumulates a smaller amount of noise relative to a large set
and thus leads to the best predictor for drug response. Following this
observation we have developed a CRF approach and applied it to
identiﬁcation of biomarkers of anti-TNF response in whole blood of
rheumatoid arthritis patients. Additionally, we have shown validity of
our approach to biomarker identiﬁcation using 3 previously published
data sets.
In the whole blood expression proﬁles of RA patients from the
AbCoN initiative, the CRF algorithm identiﬁed 8 gene transcripts that
predict response to anti-TNF treatment with 89% accuracy. The
preliminary analysis of the gene expression data identiﬁed a subset of
166 genes as candidates for predictive genes. To reﬁne the 166
informative genes into an accurate predictor, we followed several
steps for feature identiﬁcation and selection using the CRF approach.
First, we searched for the optimal RF parameters to apply in our data.
Second, using those optimal parameters, we implemented a converg-
ing RF algorithm that identiﬁed a smaller set of 40 transcripts with
accuracy of 80%. Third, using gene expression clustering and gene
importance determined by RF we developed a method for identifying
the most predictive transcripts and introduced a Gene Predictive
Index (GPI) for ranking transcripts. A ﬁnal set of best predictors
consists of 24 transcripts with an accuracy of 87%. With the GPI-based
selection we further reduced the features to 8 genes that predict anti-
TNF response with 89% accuracy. Similar accuracies are obtained for
the selected gene sets with several distinct Machine Learning
approaches. The accuracy of the predictor is also conﬁrmed by an
independent validation data set of 11 patients from the BRASS registry
however due to the small sample size and very uneven distribution of
responders versus non-responders the 95% conﬁdence intervals on
test set are very large.We note that with only 2-nonresponders callingTable 3
Performance of the CRF and RSVM predictors evaluated by the AUC measure of performanc
Method CRF
Data set # convergent genes Selected features Train AU
Golub_ALL_AML 80 8 1.000
Prostate cancer 79 5 0.963
BrCa metastasis 103 8 0.862
antTNF-response 40 8 0.890
For the training set the performance of the CRF is estimated by the OOB error and for the
method are listed in the respective columns. Both methods selection was applied to the inieveryone a responder would result in similar accuracy. Clearly, with
just a small number of independent testing cases available to us at this
time, the predictor validation requires a larger set of independent
samples.
Given a small validation set for the anti-TNF case we more closely
examine the issues that could lead to overﬁtting the 8-gene predictor.
First our gene selection process is not cross-validated explicitly due to
large computation time required for complete cross validation. How-
ever we addressed the overﬁtting problem by imposing very stringent
False Discovery Rate (FDR) requirements for independent selection
procedures. In the permutation and re-sampling procedure selecting
genes correlated with DAS28 changes the FDR is 0.0005 (see Supple-
mentary methods). In selection of genes differentially expressed in
patients from healthy controls we use Bayesian posterior probabilities
greater then 0.95. That results in selecting genes with p valueb10−6.
Since we further require overlap between the differentially expressed
genes and genes signiﬁcantly correlated with DAS28 changes, our
effective FDR is 10−10 and with 166 genes selected there is very small
likelihood (10−8) that one is a false positive. Since each step of RF run
is cross-validated this part of the procedure is cross-validated as well.
A posteriori we conﬁrmed that our 8-best genes are indeed
signiﬁcantly correlated with DAS28 changes in cross-validated per-
mutation and resampling tests.
The twenty-four best genes identiﬁed by this analysis include
genes known to be associated with rheumatoid arthritis or to have
immune-related functions. Two of those genes are histone deacety-
lases HDAC4 and HDAC5. Histone deacetylase activities are required
for innate immune cell control [24]. It has been also shown that
histone deacetylase inhibition induces antigen-speciﬁc anergy in
lymphocytes [25] and regulates the induction of MHC II class genes
[26]. Another gene, COL4A3BP (collagen, type IV, alpha-3 binding
protein), has been identiﬁed as a protein binding the autoimmune
Goodpasture syndrome autoantigen (COL4A3) [27]. COL4A3BP, also
known as CERT kinase, phosphorylates the N-terminal region of
COL4A3 and its elevated expression has been associated with immune
complex mediated pathogenesis and increased IgA deposits in
glomerular basementmembrane [28].We also identiﬁed as predictors
other genes linked to immune responses, includingMXRA7 and PGK1.
Thus identiﬁcation of several immune-related genes as features of the
best predictor further supports the validity of our approach.
The identiﬁcation of predictive biomarkers in whole blood col-
lected from RA patients demonstrates feasibility of devising a
diagnostic test assessing a patient's likelihood to beneﬁt from anti-
TNF therapy. Patients with rheumatoid arthritis (RA) are generally
treated with tumor necrosis factor (TNF)-α inhibitors as second-line
therapy if an oral medication such as methotrexate (MTX) is not
adequate to control the symptoms. If one anti-TNF therapy does not
lead to adequate symptom control, the current standard of care
dictates switching to one or more of the other approved anti-TNF
agents, followed by other biologic agents. However, the non-response
rate for the ﬁrst anti-TNF agent is over 50% and increases for
subsequent anti-TNF agents [29]. Clinical research indicates that the
non-response to a second anti-TNF therapy closely correlates with the
lack of response to the ﬁrst one. Thus a diagnostic test performede.
RSVM
C Test AUC Selected features Train AUC Test AUC
0.857 60 1.000 0.893
0.958 79 0.938 0.917
0.815 103 0.818 0.679
0.750 40 0.828 0.500
RSVM by the leave-one-out cross-validation. The predictive features selected by each
tial set of convergent genes.
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subsequent rounds of similar therapies that are likely to be ineffective
but still can have serious side effects. The biomarker predictor
identiﬁed in this investigation identiﬁes the non-responders to
therapy with ∼90% accuracy. If that level of accuracy is conﬁrmed in
a larger cohort, such a diagnostic would lead to changes in way RA is
treated. Likely every patient will initially be treated with an anti-TNF
agent, but given a diagnostic prediction of non-response the patient
could be directed to therapies with a different mechanism of action.
Additionally the small number of biomarkers identiﬁed here would
allow for implementation of the diagnostic using Q-PCR technology. In
contrast to whole genome hybridization-based expression proﬁling,
Q-PCR is more sensitive and robust. Recently a Q-PCR-based AlloMap®
from Expression Diagnostics (XDx), measuring gene expression in the
peripheral bloodmononuclear cells, has been approved formonitoring
for rejection the heart transplant patients. Our investigation indicates
that a similar diagnostic test can be developed for guiding the choice of
therapy for RA patients.
We have shown the validity of CRF approach by applying it to three
previously published data sets. In the well-studied data set of primary
breast cancer tumors, the CRF algorithm identiﬁed 8-gene transcripts
that predict progression to metastasis with 86% accuracy. This data set
was investigated by the pioneering work of van't Veer et al. [12]. The
original analysis of this data identiﬁed 70-genes that predicted
metastasis with 83% accuracy on the training set of samples and a
similar accuracy on a test set. The application of the CRF approach has
identiﬁed in this data set amuch smaller set of only 8 genes that predict
metastasis with accuracy of 86% for the training set and a similar
accuracy for the test set. Several other gene sets predictive of
progression to metastasis have been evaluated in the literature with a
similar predictive power [30], including the 21-gene assay used by
Oncotype DX, the alternative to the Mammaprint diagnostic. We note
that our 8-gene set is also considerably smaller than the Oncotype DX
diagnostic set. The 8-gene set has only one gene, MMP9, in common
with the original 70-gene signature. However, the lack of a substantial
overlap among gene sets does not mean that the classiﬁer is not robust,
as has been recently shown for the70-gene, 21-gene andwoundhealing
signatures applied to prediction of breast cancer progression [17].
The 8 genes selected as the best predictor of progression to
metastasis are: MMP9, CA9, INPP5J, NUP210, FBP1, IFITM1, SLC37A1
and TSPYL5. Among those eight genes two have been recently linked
to the invasive (i.e. metastatic) breast cancer phonotype. It has been
recently shown that up-regulation of several metalloproteinases
(MMPs), including MMP9, is associated with the metastatic pheno-
type of breast cancer [31]. Additionally the up-regulation of the CA9
correlates with fast progression to metastasis [32].
We have demonstrated that the CRF approach, for selection of non-
redundant molecular features predictive of a disease progression or
treatment response, identiﬁes the minimal number of features with a
maximal predictive power. We note that once the non-redundant
predictive features are identiﬁed, many of the machine learning
approaches, such as SVMs and neural nets have predictive power
similar to RF.We have compared the CRF and RSVMapproach to feature
selection. RSVM uses a recursive feature selection method representa-
tive of other recursive approaches. The comparisonwas performed on 4
very different sets of proﬁling data, each consisting of training and
independent testing sets of samples. In each case only the testing set of
samples were used for the identiﬁcation of predictive features. Both
methods constructed predictors with comparable performance as
measured by the area under the ROC curve. The CRF consistently
identiﬁed much smaller number of features than RSVM, and had
performance somewhat better for all but one testing set of data used for
comparison. In any disease or therapy setting, the selection of just a few
gene features would allow for a straightforward translation of the
signature gene set discovered with genome-wide proﬁling, such as
Affymetrix chips, to standard Q-PCR or sequencing technologies thathave higher accuracy and lower costs. Thus we believe that the CRF
methodwill help put into practice futuremolecular diagnostics thatwill
assist in the implementation of individualized patient treatment.
Materials and methods
Patient data
TNF-block response prediction
Patient blood samples were collected pre-treatment in PAXgene
tubes. Whole blood RNA was extracted and proﬁled using standard
protocols on Affymetrix hgu133plus2 chips. For details see Supple-
mentary materials and methods. Rheumatoid arthritis patients with
active disease and naïve to TNF-blocking therapy were enlisted in the
study. Response to TNF-blocking therapy was assessed after 14 weeks
of treatment. Twenty-four patients were classiﬁed as responders and
twenty-two as non-responders according to the EULAR classiﬁcation
[33,34]. These data are available from the Gene Expression Omnibus
(GEO) database at NCBI and has the accession number GSE15258.
Breast cancer progression to metastasis
The patient population description can be found in the original
paper [12] and the supplementary material available from the web site
http://www.rii.com/publications/default.html. Brieﬂy, the training set
consist of 78 samples with 34 samples belonging to patients with
progression to metastasis after less than 5 years and 44 samples from
patients with the onset of metastasis more than 5 years after the ﬁrst
diagnosis. The test set contains 19 samples with 12 patients progressing
to metastasis within 5 years and 7 patients with less aggressive disease.
Leukemia data set
Data for the testing and training sets were downloaded from
the Broad Institute Cancer Program site: http://www.broad.mit.edu/
cgi-bin/cancer/datasets.cgi. Both molecular and patient data are
available from the site.
Prostate cancer data set
Data were downloaded from the Broad Institute Cancer Program
site: http://www.broad.mit.edu/cgi-bin/cancer/datasets.cgi. We
have randomly selected for testing the following samples: N11, N17,
N20, N24, N25, N34, N35, N44, N59, N62, T05, T16, T17, T20, T21, T24,
T28, T31, T36, T37, T38, T46,
Initial data processing for anti-TNF response prediction
Gene expression was analyzed starting with GCRMA normalization.
Transcripts from the AbCoN training set was ﬁrst reduced to those
considered present in at least 50% in the samples from the same
phenotypic group. Second, only transcripts that were signiﬁcantly
correlated with score for disease progression were selected. The signi-
ﬁcancewas assessed using re-sampling andpermutation as described in
Supplementarymaterials andmethods. Third, only transcripts thatwere
signiﬁcantly different between responder, non-responder and healthy
controls groups were considered. In the last and ﬁnal step only
transcripts with high expression and representing known genes in the
ENTREZ database were selected. Details of this analysis are in
Supplementary materials and methods. All analysis were done using
the packages from R and Bioconductor [35].
Initial processing for breast cancer metastasis prediction
We downloaded expression and clinical patient data from the
website http://www.rii.com/publications/default.html. First a set of
genes that are signiﬁcantly different from the reference sample was
selected as described in the original paper [12]. For the identiﬁcation
of the most relevant transcripts, the ratios of intensities were ﬁtted to
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of the ﬁt was assessed by re-sampling and permutation tests similar to
the ones applied to the anti-TNF data (see Supplementary materials
and methods). This preprocessing selected 223 gene transcripts
relevant to metastasis prediction. All calculations were done using R
statistical programming language.
Initial processing of the leukemia data set
This data set is available as normalized and background corrected
intensities. All the negative intensity valueswere replacedby1 and then
data was log2 transformed. Using only the training set we have
identiﬁed those transcripts thatwerepresent in at least 50%of theALLor
50% of AML samples. This procedure identiﬁed 2231 transcripts. For the
identiﬁcation of the most relevant transcripts, the log2-transformed
intensities were ﬁtted to the logistic regression model of ALL-AML
status. The signiﬁcance of the ﬁt was assessed by re-sampling and
permutation tests as are described for BrCa metastasis set in
Supplementary materials and methods. This procedure identiﬁed 516
transcripts that are candidate biomarkers analyzed by the CRF method.
Initial processing of the prostate cancer data set
These data are available as raw intensity CEL ﬁles. We normalized
the data using the GCRMA procedure and using the MAS5 presence/
absence calls identiﬁed genes present in at least 50% of the tumor or
50% of the normal samples. This step identiﬁed 1783 transcripts. For
identiﬁcation of the most relevant transcripts, the log2-transformed
intensities were ﬁtted to the logistic regression model of tumor-
normal status. The signiﬁcance of the ﬁt was assessed by re-sampling
and permutation tests as are described for BrCa metastasis set in
Supplementary materials and methods. This procedure identiﬁed 921
transcripts that are candidate biomarkers analyzedby the CRFmethod.
Other classiﬁcation algorithms
The classiﬁcation algorithms that were run in comparison to RF
include. (1) k nearest neighbor classiﬁer (kNN) is run with k={1, 3, 5,
…, 21} and k with the smallest error was chosen. (2) SVM [36] with
radial kernel was run with combinations of cost parameter c={1, 2, 4}
and theparameterγ={2−1/18, 1/18, 2/18} as suggested byGentleman
et al. [37]. Random forest was run with 10,000 trees and default mtry.
The analysis was performed using MLInterfaces package in R. We have
used the RSVM.R functions as provided by the authors on the web site
http://www.stanford.edu/group/wonglab/RSVMpage/R-SVM.html.
The CRF method has been implemented in R and is available from
authors upon request: Jadwiga.Bienkowska@biogenidec.com.
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